Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2025-03-24 Purchase |
2025-03-25 6:32 pm |
Monte Rosa Therapeutics Inc. | GLUE | Leo Chandra P. Director |
10,000 | $5.8383 | $58,383 | 10,000 (Direct) |
View |
| 2024-10-28 Sale |
2024-10-30 4:35 pm |
Monte Rosa Therapeutics Inc. | GLUE | Versant Venture Capital VI L.P. Versant Ventures VI GP L.P. Versant Ventures VI GP-GP LLC Versant Vantage I L.P. Versant Vantage I GP L.P. Versant Vantage I GP-GP LLC 10% Owner |
157,895 | $9.4432 | $1,491,041 | 7,137,269 (Indirect Direct) |
View |
| 2024-09-20 Sale |
2024-09-24 4:40 pm |
Monte Rosa Therapeutics Inc. | GLUE | Versant Venture Capital VI L.P. Versant Ventures VI GP L.P. Versant Ventures VI GP-GP LLC Versant Vantage I L.P. Versant Vantage I GP L.P. Versant Vantage I GP-GP LLC 10% Owner |
1,132,566 | $6.5296 | $7,395,203 | 7,197,274 (Indirect Direct) |
View |
| 2024-09-11 Sale |
2024-09-13 6:44 pm |
Monte Rosa Therapeutics Inc. | GLUE | Versant Venture Capital VI L.P. Versant Ventures VI GP L.P. Versant Ventures VI GP-GP LLC Versant Vantage I L.P. Versant Vantage I GP L.P. Versant Vantage I GP-GP LLC 10% Owner |
567,213 | $6.0027 | $3,404,791 | 8,329,840 (Indirect Direct) |
View |
| 2024-07-05 Sale |
2024-07-09 4:15 pm |
Monte Rosa Therapeutics Inc. | GLUE | Dunn Edmund Principal Accounting Officer |
1,610 | $3.8301 | $6,166 | 13,944 (Direct) |
View |
| 2024-06-03 Sale |
2024-06-05 4:10 pm |
Monte Rosa Therapeutics Inc. | GLUE | Dunn Edmund Principal Accounting Officer |
1,207 | $4.0396 | $4,876 | 15,554 (Direct) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
| 2025-01-02 Option Award |
2025-01-06 4:15 pm |
N/A 2035-01-01 |
Monte Rosa Therapeutics Inc. | GLUE | Nickson Philip Chief Business & Legal Officer |
197,000 | $0 | 197,000 (Direct) |
View |
| 2025-01-02 Option Award |
2025-01-06 4:15 pm |
N/A 2035-01-01 |
Monte Rosa Therapeutics Inc. | GLUE | Dunn Edmund Principal Accounting Officer |
65,250 | $0 | 79,194 (Direct) |
View |
| 2025-01-02 Option Award |
2025-01-06 4:15 pm |
N/A 2035-01-01 |
Monte Rosa Therapeutics Inc. | GLUE | Janku Filip Chief Medical Officer |
197,000 | $0 | 206,189 (Direct) |
View |
| 2025-01-02 Option Award |
2025-01-06 4:15 pm |
N/A 2035-01-01 |
Monte Rosa Therapeutics Inc. | GLUE | Champoux Jennifer Chief Operating Officer |
165,000 | $0 | 165,000 (Direct) |
View |
| 2025-01-02 Option Award |
2025-01-06 4:15 pm |
N/A 2035-01-01 |
Monte Rosa Therapeutics Inc. | GLUE | Warmuth Markus President & CEO |
703,000 | $0 | 1,119,538 (Direct) |
View |
| 2025-01-02 Option Award |
2025-01-06 4:15 pm |
N/A 2035-01-01 |
Monte Rosa Therapeutics Inc. | GLUE | Townson Sharon Chief Scientific Officer |
197,000 | $0 | 197,000 (Direct) |
View |
| 2024-12-11 Option Award |
2024-12-13 09:05 am |
N/A 2034-12-10 |
Monte Rosa Therapeutics Inc. | GLUE | Hughes Eric A Director |
44,200 | $0 | 44,200 (Direct) |
View |
| 2024-10-28 Other |
2024-10-30 4:35 pm |
N/A N/A |
Monte Rosa Therapeutics Inc. | GLUE | Versant Venture Capital VI L.P. Versant Ventures VI GP L.P. Versant Ventures VI GP-GP LLC Versant Vantage I L.P. Versant Vantage I GP L.P. Versant Vantage I GP-GP LLC 10% Owner |
1,435,402 | $0 | 7,137,269 (Direct) |
View |
| 2024-09-13 Option Award |
2024-09-13 4:30 pm |
N/A 2032-10-04 |
Monte Rosa Therapeutics Inc. | GLUE | Janku Filip Chief Medical Officer |
30,000 | $0 | 30,000 (Direct) |
View |
| 2024-06-12 Option Award |
2024-06-13 8:12 pm |
N/A 2034-06-12 |
Monte Rosa Therapeutics Inc. | GLUE | Behbahani Ali Director 10% Owner |
22,100 | $0 | 22,100 (Direct) |
View |
| 2024-06-12 Option Award |
2024-06-13 4:30 pm |
N/A 2034-06-12 |
Monte Rosa Therapeutics Inc. | GLUE | SCHIFF ANDREW N Director |
22,100 | $0 | 22,100 (Direct) |
View |
| 2024-06-12 Option Award |
2024-06-13 4:30 pm |
N/A 2034-06-12 |
Monte Rosa Therapeutics Inc. | GLUE | Siu Christine Director |
22,100 | $0 | 22,100 (Direct) |
View |
| 2024-06-12 Option Award |
2024-06-13 4:30 pm |
N/A 2034-06-12 |
Monte Rosa Therapeutics Inc. | GLUE | Skvarka Jan Director |
22,100 | $0 | 22,100 (Direct) |
View |
| 2024-06-12 Option Award |
2024-06-13 4:30 pm |
N/A 2034-06-12 |
Monte Rosa Therapeutics Inc. | GLUE | Manning Anthony M. Director |
22,100 | $0 | 22,100 (Direct) |
View |
| 2024-06-12 Option Award |
2024-06-13 4:30 pm |
N/A 2034-06-12 |
Monte Rosa Therapeutics Inc. | GLUE | Blackwell Kimberly Director |
22,100 | $0 | 22,100 (Direct) |
View |
| 2024-06-03 Option Award |
2024-06-05 4:10 pm |
N/A 2034-06-03 |
Monte Rosa Therapeutics Inc. | GLUE | Nickson Philip Chief Business & Legal Officer |
40,000 | $0 | 40,000 (Direct) |
View |
| 2024-06-03 Option Award |
2024-06-05 4:10 pm |
N/A 2034-06-03 |
Monte Rosa Therapeutics Inc. | GLUE | Townson Sharon Chief Scientific Officer |
40,000 | $0 | 40,000 (Direct) |
View |
| 2024-06-03 Option Award |
2024-06-05 4:10 pm |
N/A 2034-06-03 |
Monte Rosa Therapeutics Inc. | GLUE | Champoux Jennifer Chief Operating Officer |
40,000 | $0 | 40,000 (Direct) |
View |
Ownership |
2024-06-05 4:05 pm |
N/A 2031-04-12 |
Monte Rosa Therapeutics Inc. | GLUE | Champoux Jennifer Chief Operating Officer |
0 | $0 | 305,120 (Direct) |
View |
Ownership |
2024-06-05 4:05 pm |
N/A 2030-08-14 |
Monte Rosa Therapeutics Inc. | GLUE | Townson Sharon Chief Scientific Officer |
0 | $0 | 517,851 (Direct) |
View |
| 2024-01-02 Option Award |
2024-01-04 4:15 pm |
N/A 2034-01-01 |
Monte Rosa Therapeutics Inc. | GLUE | Warmuth Markus President & CEO |
346,000 | $0 | 346,000 (Direct) |
View |
| 2024-01-02 Option Award |
2024-01-04 4:15 pm |
N/A 2034-01-01 |
Monte Rosa Therapeutics Inc. | GLUE | Wallace Owen B. Chief Scientific Officer |
119,000 | $0 | 124,266 (Direct) |
View |
| 2024-01-02 Option Award |
2024-01-04 4:15 pm |
N/A 2034-01-01 |
Monte Rosa Therapeutics Inc. | GLUE | Jones Jullian G Chief Business Officer |
79,000 | $0 | 79,000 (Direct) |
View |
| 2024-01-02 Option Award |
2024-01-04 4:15 pm |
N/A 2034-01-01 |
Monte Rosa Therapeutics Inc. | GLUE | Janku Filip Chief Medical Officer |
121,000 | $0 | 126,252 (Direct) |
View |
| 2024-01-02 Option Award |
2024-01-04 4:15 pm |
N/A 2034-01-01 |
Monte Rosa Therapeutics Inc. | GLUE | Nickson Philip General Counsel |
109,000 | $0 | 109,000 (Direct) |
View |
| 2024-01-02 Option Award |
2024-01-04 4:15 pm |
N/A 2034-01-01 |
Monte Rosa Therapeutics Inc. | GLUE | Dunn Edmund Principal Accounting Officer |
60,900 | $0 | 60,900 (Direct) |
View |
Ownership |
2023-08-18 4:00 pm |
N/A N/A |
Monte Rosa Therapeutics Inc. | GLUE | Dunn Edmund Principal Accounting Officer |
0 | $0 | 92,876 (Direct) |
View |
| 2023-07-25 Option Award |
2023-07-26 4:10 pm |
N/A 2033-07-24 |
Monte Rosa Therapeutics Inc. | GLUE | Manning Anthony M. Director |
41,000 | $0 | 41,000 (Direct) |
View |
| 2023-06-14 Option Award |
2023-06-15 4:42 pm |
N/A 2033-06-13 |
Monte Rosa Therapeutics Inc. | GLUE | Behbahani Ali Director 10% Owner |
20,500 | $0 | 20,500 (Direct) |
View |
| 2023-06-14 Option Award |
2023-06-15 4:29 pm |
N/A 2033-06-13 |
Monte Rosa Therapeutics Inc. | GLUE | Skvarka Jan Director |
20,500 | $0 | 20,500 (Direct) |
View |
| 2023-06-14 Option Award |
2023-06-15 4:28 pm |
N/A 2033-06-13 |
Monte Rosa Therapeutics Inc. | GLUE | Siu Christine Director |
20,500 | $0 | 20,500 (Direct) |
View |
| 2023-06-14 Option Award |
2023-06-15 4:28 pm |
N/A 2033-06-13 |
Monte Rosa Therapeutics Inc. | GLUE | SCHIFF ANDREW N Director |
20,500 | $0 | 20,500 (Direct) |
View |
| 2023-06-14 Option Award |
2023-06-15 4:27 pm |
N/A 2033-06-13 |
Monte Rosa Therapeutics Inc. | GLUE | Mayweg Alexander Director |
20,500 | $0 | 20,500 (Direct) |
View |